Coral Laboratories Ltd. (BSE: 524506) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹191 Cr, it ranks #2,704 by market cap among the 6,137 Indian listed companies on FinBizNet, and #57 of 86 in Medicinal Chemicals and Botanical Products. At ₹533.90 (as of 25 Oct 2026), the share price is 21.4% below its 52-week high of ₹679.00 and 48.3% above its 52-week low of ₹360.00. The share price is down 3.3% over one year and down 15.1% over three months.
| Current Price | ₹533.90 |
|---|---|
| Market Cap | ₹191 Cr |
| BSE Code | 524506 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 11.6 |
| Return on Equity | 7.98% |
| Return on Assets | 3.58% |
| 52-Week Range | ₹360.00 – ₹679.00 |
| 1-Year Price Change | -3.3% |
| 3-Month Price Change | -15.1% |
| Beta (1Y) | 0.41 |
| Dividend Yield | 0.37% |
| Headquarters | Mumbai, Maharashtra |
| Website | corallab.com |
| Revenue | ₹30 Cr |
|---|---|
| Net Profit | ₹5 Cr |
| Net Margin | 18.2% |
| EPS (Basic) | ₹15.08 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethiopia, and internationally. The company offers non-sterile products, including antibiotics/antibacterial, antifungal, gastro-intestinal drugs, antiemetic, analgesics/antipyretic/anti-inflammatory, antispasmodic, muscle relaxants, cough suppressant/expectorant, anticold, antiallergic, anti-asthmatic, cardiovascular medicines, anti-diabetic, anthelmentic, anti-protozoal/anti-amebic, antimalarial drugs, antipsychotic drugs, and thyroid products; topical, oral antiseptic, and calcium preparations; mouthwashes; nutritional, protein, and iron supplements; kits; appetizers; and other products. It also provides sterile products, such as small volume liquid, cephalosporin, betalactam, and lyophilized injectables; eye, ear, and nose drops; nasal sprays and metered dose inhalers; and large volume parenteral. In addition, the company offers various nutraceutical products, such as dietary supplements, herbal/
1. Formulations-This segment manufactures and sells pharmaceutical formulations.
1. Pharmaceutical Formulations-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Coral Laboratories Ltd. | ₹191 Cr | 11.6 | 7.98% | ₹30 Cr | -3.3% |
Listed by market capitalisation. Ratios are shown for context only.
Coral Laboratories Ltd. is trading at ₹533.90, with a market capitalisation of ₹191 Cr.
Coral Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Coral Laboratories Ltd. has a P/E of 11.6 and a return on equity of 7.98%.
Coral Laboratories Ltd. is listed on the BSE under the scrip code 524506.
Coral Laboratories Ltd.'s share price is down 3.3% over one year and down 15.1% over three months. Its 52-week range is ₹360.00 to ₹679.00.
In Q1 FY27, Coral Laboratories Ltd. reported revenue of ₹30 Cr and net profit of ₹5 Cr, with basic EPS of ₹15.08 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.